INFECTION LANDSCAPE IN PATIENTS WITH CLL TREATED WITH VENETOCLAX-BASED REGIMENS COMPARED TO THE SECOND-GENERATION BRUTON TYROSINE KINASE INHIBITORS: MULTICENTRE, OBSERVATIONAL STUDY (IMAGINE)

This study aims to compare, in a real-world setting, the cumulative incidence of severe infections (G3-G5) in CLL patients treated with venetoclax-based regimens or second-generation BTKi within the centers of ERIC. 

The study will consist of two cohorts with 24-month follow-up. 

Cohort A – treatment-naïve CLL patients treated in 1st line with venetoclax-based regimens or second-generation BTKi.

Cohort B – relapsed/refractory CLL patients treated in 2nd line with venetoclax-based regimens or second-generation BTKi, without prior chemoimmunotherapy (CIT)


Sign in to Google to save your progress. Learn more
Email *
Name and Last Name: *
Name of your institution: *
Country: *
Next
Clear form
Never submit passwords through Google Forms.
This form was created inside of Avoris Travel.

Does this form look suspicious? Report

Google Forms